Lumosa Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	181.59	235.49	425.25	516.85	840.32
Short-Term Investments	616.74	1,117	419.06	667.67	589.89
Trading Asset Securities	-	-	-	-	21.89
Cash & Short-Term Investments	798.34	1,353	844.31	1,185	1,452
Cash Growth	-40.99%	60.23%	-28.72%	-18.43%	14.26%
Accounts Receivable	12.9	20.63	12	14	9.69
Other Receivables	11.48	19.16	18.13	17.98	17.01
Receivables	24.38	39.79	30.14	31.98	26.7
Inventory	98.78	97.78	103.91	108.68	82.39
Prepaid Expenses	44.59	46.64	65.66	60.88	59.17
Other Current Assets	0	0.02	0.02	-	0.13
Total Current Assets	966.1	1,537	1,044	1,386	1,620
Property, Plant & Equipment	14.44	19.68	27.53	7.66	13
Long-Term Investments	669	575.42	583.79	464.72	671.32
Other Intangible Assets	0.37	0.49	0.6	26.93	43.57
Other Long-Term Assets	0.32	0.32	0.32	0.32	0.32
Total Assets	1,650	2,133	1,656	1,886	2,349
Accounts Payable	1.31	1.42	1.49	12.25	14.5
Accrued Expenses	39.33	36.7	54.41	33.62	43.26
Current Portion of Leases	6.92	4.2	4.49	4.33	5.4
Current Unearned Revenue	2.8	3.04	3.04	6.88	4.68
Other Current Liabilities	80.68	155.83	156.14	158.28	156.18
Total Current Liabilities	131.04	201.18	219.58	215.36	224.03
Long-Term Leases	-	4.28	8.12	0.36	6.08
Total Liabilities	131.04	205.46	227.69	215.72	230.11
Common Stock	1,688	1,689	1,650	1,631	1,632
Additional Paid-In Capital	265.83	2,223	1,363	1,268	1,271
Retained Earnings	-340.54	-1,919	-1,494	-1,256	-761.44
Treasury Stock	-56.8	-	-	-	-
Comprehensive Income & Other	-47.22	-81.59	-117.45	-13.53	-22.98
Total Common Equity	1,509	1,912	1,401	1,630	2,119
Minority Interest	9.76	15.84	27.89	40.18	-
Shareholders' Equity	1,519	1,928	1,429	1,670	2,119
Total Liabilities & Equity	1,650	2,133	1,656	1,886	2,349
Total Debt	6.92	8.48	12.61	4.69	11.49
Net Cash (Debt)	791.42	1,344	831.7	1,180	1,441
Net Cash Growth	-41.13%	61.64%	-29.51%	-18.10%	14.89%
Net Cash Per Share	4.76	8.22	5.12	7.26	9.55
Filing Date Shares Outstanding	167.49	168.9	164.97	163.1	163.15
Total Common Shares Outstanding	167.49	168.9	164.97	163.1	163.15
Working Capital	835.06	1,336	824.46	1,171	1,396
Book Value Per Share	9.01	11.32	8.49	9.99	12.99
Tangible Book Value	1,509	1,911	1,400	1,603	2,075
Tangible Book Value Per Share	9.01	11.32	8.49	9.83	12.72
Machinery	41.78	41.77	41.5	31.82	29.53
Leasehold Improvements	3.21	3.21	3.21	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.